MedPath

Primaquine

Generic Name
Primaquine
Drug Type
Small Molecule
Chemical Formula
C15H21N3O
CAS Number
90-34-6
Unique Ingredient Identifier
MVR3634GX1
Background

An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Adverse effects include anemias and GI disturbances. (From Martindale, The Extra Pharmacopeia, 30th ed, p404)

Indication

For the treatment of malaria.

Associated Conditions
Malaria, Malaria caused by Plasmodium ovale, Malaria caused by plasmodium vivax, Pneumocystis Jirovecii Pneumonia
Clinical Trials
Related News

An Interventional Study to Compare the Efficacy and Safety of Tafenoquine (TQ) and Primaquine (PQ) When Either Are Taken Together With Chloroquine (CQ) for the Treatment of P. Vivax Malaria in Indian Participants Aged 2 Years and Older

Phase 3
Recruiting
Conditions
Malaria, Vivax
Interventions
First Posted Date
2024-10-30
Last Posted Date
2024-12-13
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
300
Registration Number
NCT06666491
Locations
🇮🇳

GSK Investigational Site, Surat, India

A Study to Evaluate Antimalarial Activity and Safety of MK-7602 in Healthy Adults (MK-7602-003)

Phase 1
Completed
Conditions
Malaria
Interventions
Other: Plasmodium falciparum
First Posted Date
2024-03-06
Last Posted Date
2025-01-13
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
16
Registration Number
NCT06294912
Locations
🇦🇺

USC Clinical Trials Brisbane (South Bank) ( Site 0001), South Brisbane, South Australia, Australia

Postpartum Primaquine in Breast Milk

Phase 4
Not yet recruiting
Conditions
Postpartum Women
Interventions
First Posted Date
2024-01-05
Last Posted Date
2024-03-19
Lead Sponsor
University of Oxford
Target Recruit Count
12
Registration Number
NCT06191458
Locations
🇹🇭

Shoklo Malaria Research Unit (SMRU), Mae Ramat, Tak, Thailand

A Revised Tafenoquine Dose to Improve Radical Cure for Vivax Malaria

Phase 3
Recruiting
Conditions
Vivax Malaria
Interventions
First Posted Date
2023-11-28
Last Posted Date
2025-04-18
Lead Sponsor
Menzies School of Health Research
Target Recruit Count
1090
Registration Number
NCT06148792
Locations
🇧🇷

Dr Marcus Lacerda, Manaus, Brazil

🇪🇹

Arba Minch General Hospital, Arba Minch, Ethiopia

🇮🇩

Dr Rini Poespoprodjo, Timika, Indonesia

and more 1 locations

Therapeutic Efficacy of Chloroquine Plus Primaquine in the Treatment of Uncomplicated Plasmodium Vivax

Phase 4
Completed
Conditions
Malaria
Vivax Malaria
Chloroquine
Efficacy
Interventions
First Posted Date
2023-09-21
Last Posted Date
2023-09-22
Lead Sponsor
Dinka Dugassa
Target Recruit Count
100
Registration Number
NCT06044805
Locations
🇪🇹

Shecha Health Center, Arba Minch, South Ethiopia, Ethiopia

Combination Momordica Charantia Extract and Primaquine Againts Plasmodium Falciparum Uncomplicated and Plasmodium Vivax Uncomplicated Treatment in Manokwari, West Papua

Phase 2
Completed
Conditions
Malaria, Vivax
Infections
Malaria,Falciparum
Uncomplicated Malaria
Malaria
Uncomplicated Plasmodium Falciparum
Interventions
Other: Momordica Charantia Extract
First Posted Date
2023-09-13
Last Posted Date
2023-09-13
Lead Sponsor
Syamsudin Abdillah,Ph.D, Pharm D
Target Recruit Count
50
Registration Number
NCT06036030
Locations
🇮🇩

Manokwari Regional General Hospital, Manokwari, West Papua, Indonesia

TES of Chloroquine for Pv in the Philippines in 2016

Completed
Conditions
Malaria
Recrudescence
Vivax Malaria
Interventions
First Posted Date
2023-07-25
Last Posted Date
2023-07-25
Lead Sponsor
Research Institute for Tropical Medicine, Philippines
Target Recruit Count
74
Registration Number
NCT05958797

TES of Artemether-lumefantrine for Pf in the Philippines in 2017-2018

Completed
Conditions
Malaria,Falciparum
Malaria Recrudescence
Interventions
First Posted Date
2023-07-25
Last Posted Date
2023-07-25
Lead Sponsor
Research Institute for Tropical Medicine, Philippines
Target Recruit Count
80
Registration Number
NCT05958810

TES of Artemether-lumefantrine for Pf in the Philippines in 2015

Completed
Conditions
Malaria,Falciparum
Malaria Recrudescence
Interventions
First Posted Date
2023-07-24
Last Posted Date
2023-07-24
Lead Sponsor
Research Institute for Tropical Medicine, Philippines
Target Recruit Count
82
Registration Number
NCT05958693

Momordica Charantia and Dihydroartemisinin-piperaquined-primaquine for Uncomplicated Plasmodium Falciparum Malaria Patients in Southwest Sumba Regency

Phase 2
Completed
Conditions
Uncomplicated Plasmodium Falciparum
Interventions
First Posted Date
2023-04-25
Last Posted Date
2023-05-16
Lead Sponsor
Syamsudin Abdillah,Ph.D, Pharm D
Target Recruit Count
36
Registration Number
NCT05829187
Locations
🇮🇩

Kori Puskesmas, Tambolaka, East Nusa Tenggara, Indonesia

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy